SR9243

• CAT Number: I002055
• CAS Number: 1613028-81-1
• Molecular Formula: C31H32BrNO4S2
• Molecular Weight: 626.624
• Purity: ≥95%
• Target: LXR
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: N-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyl-N-[[4-(3-methylsulfonylphenyl)phenyl]methyl]benzenesulfonamide
• InChI: InChI=1S/C31H32BrNO4S2/c1-22-17-23(2)31(24(3)18-22)39(36,37)33(16-15-25-7-5-9-29(32)19-25)21-26-11-13-27(14-12-26)28-8-6-10-30(20-28)38(4,34)35/h5-14,17-20H,15-16,21H2,1-4H3
• InChIKey: FYQFEJFTCLKXTQ-UHFFFAOYSA-N
• SMILES: CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CCC2=CC(=CC=C2)Br)CC3=CC=C(C=C3)C4=CC(=CC=C4)S(=O)(=O)C)C

SR9243 (CAT: I002055) is a notable compound classified as a liver X receptor (LXR) inverse agonist. Its unique mode of action involves inducing the interaction between LXR and its corepressor. This interaction has implications in modulating gene expression related to lipid metabolism and cholesterol homeostasis. SR9243 exhibits intriguing anticancer activity by selectively targeting the Warburg effect (enhanced glycolysis) and lipogenesis, processes often upregulated in cancer cells to support rapid growth. This selective modulation offers a potential avenue for developing innovative strategies in cancer therapy.

Reference

[1]. Flaveny CA, et al. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell. 2015 Jun 24. pii: S1535-6108(15)00183-X.